new Delhi: AIIMS on Monday started recruiting volunteers for human trials of the country-developed Kovid-19 vaccine ‘Kovaxine’. This information was given by Randeep Guleria, director of All India Institute of Medical Sciences (AIIMS). He also said that there is no more evidence of community spread of Kovid-19 at the national level but there are “hotspots, even in cities where there is an increase in cases, there is a possibility that there is local spread in those areas is.”
Asked whether the cases of Kovid-19 reached the peak in India, Guleria said, “I believe they have reached the peak in some areas.” This seems to be happening in Delhi as cases have started to decrease significantly. But it is yet to reach the peak in some areas.
Guleria said that infection cases are increasing in some states, they will reach the peak a little later. In some states in the south, in some places in central Mumbai and Ahmedabad, there seems to be a decrease in cases.
He said, “But reaching the peak and then beginning to decrease does not mean that you will be lax in your efforts. In many cities outside India, especially in the US, when people felt that the situation at the peak of the cases had ended, they started violating the rules of physical distance, wearing masks and the cases increased again.
‘Covaxin’ is being developed by Bharat Biotech based in Hyderabad in collaboration with ICMR and National Institute of Virology. The Drug Controller General of India had recently approved human trials of the vaccine. Asked when the vaccine will be available, Guleria said that it will depend on whether everything works correctly.
He said, “It is possible that we will say that the vaccine is safe and then if we know that it is not giving much effect then we will have to do something more which may take a few months.”
Guleria said, “Therefore, it is difficult to tell the exact time of vaccine availability. If everything works well then by the end of the year or early next year we may be in a position to say that we can start manufacturing vaccines. ”
Guleria said, “The phase of human trials has started and it is very praiseworthy because it is an indigenous vaccine.” We do not do research and development in India.
He said that creating a new vaccine is a major achievement for India “and now we are in the field of research and development, making our own vaccine and then succeeding in mass production.”
Guleria said, “We have a very good position in mass production. If any vaccine comes from any part of the world, India will be involved in its production because 60 percent or more of the world’s vaccines are being manufactured in India.